跳至主要内容
临床试验/NCT02747303
NCT02747303招募中2 期

The Clinical Relevance of Margins in Frameless Stereotactic Radiosurgery for Intact Brain Metastases: a Randomized Trial of 0 vs 2 mm Margins

University of Chicago2 个研究点 分布在 1 个国家目标入组 166 人开始时间: 2023年9月5日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
招募中
入组人数
166
试验地点
2
主要终点
Progression free survival (PFS) rates estimated by the Kaplan-Meier method at 6 months

研究概览

简要总结

This is a randomized study to determine if not treating planning target volume (PTV) margins during radiation therapy worsens progression free survival rates in patients with brain metastases.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients (≥ 18 years old) with an ECOG Performance Status 0-2 and a life expectancy of 3 months or more.
  • Histologically confirmed systemic malignancy with gadolinium contrast-enhanced MRI scan demonstrating 1-5 intraparenchymal brain metastases.
  • Well-circumscribed, measureable intraparenchymal brain lesion(s) with maximum tumor diameter ≤3.0 cm. If multiple lesions are present, the other(s) must not exceed 3.0 cm in maximum diameter. At least one lesion must be ≥1.0 cm in maximum diameter and ≥0.5 cm in a perpendicular diameter to be considered measurable disease.
  • Negative urine or serum pregnancy test done ≤ 14 days prior to CT simulation, for women of child-bearing potential only.
  • Ability to understand and willingness to sign a written informed consent document.

排除标准

  • Diagnosis of germ cell tumor, small cell carcinoma or hematologic malignancy.
  • Metastases in the brain stem, midbrain, pons, medulla, or within 7 mm of the optic apparatus (optic nerves, chiasm and optic tracts).
  • Diagnosis of leptomeningeal disease.
  • Prior cranial radiotherapy within 90 days of trial enrollment or prior SRS at any time to any lesion to be treated on protocol
  • Chemotherapy (including oral agents and targeted agents) or immunotherapy given within 14 days of SRS. Hormonal therapy is permitted. For Her2+ breast cancer patients, anti-Her2 therapy cannot be given within 14 days of SRS. Patients who are scheduled to receive trastuzumab emtansine after SRS cannot be enrolled.
  • Contraindications to gadolinium contrast-enhanced MRI (eg, non-compatible pacemaker, eGFR<30, gadolinium allergy).

研究组 & 干预措施

Stereotactic Radiosurgery to 0 mm GTV to PTV margins

Experimental

干预措施: Stereotactic Radiosurgery (Procedure)

Stereotactic Radiosurgery to 2 mm GTV to PTV margins

Active Comparator

干预措施: Stereotactic Radiosurgery (Procedure)

结局指标

主要结局

Progression free survival (PFS) rates estimated by the Kaplan-Meier method at 6 months

时间窗: 6 months

Progression free survival (PFS) rates will be estimated by the Kaplan-Meier method and the 0-mm and 2-mm groups will be compared via the log-rank statistic with a one-sided test of significance, using follow-up data up to 6 months.

次要结局

  • Progression free survival (PFS) rates estimated by the Kaplan-Meier method(2 years)
  • Overall survival rates(2 years)
  • Rates of radiation necrosis(2 years)
  • Rates of pseudoprogression(2 years)
  • Local failure rates(2 years)
  • Rate of acute central nervous system (CNS) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 grade 2 and higher toxicities(90 days)
  • Rate of late central nervous system (CNS) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 grade 2 and higher toxicities(2 years)
  • Rates of distant intracranial failure(2 years)
  • Rates of salvage therapy(2 years)
  • Association between dose and risk of radionecrosis or pseudoprogression(2 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验